



Brian Steingo, MD ❖ Carlos Azaret, MD ❖ Abraham Chamely, MD ❖ Barry Cutler, MD

CLINICAL COORDINATORS: ❖ Michele Fistel, LPN, CCRC  
❖ Adriana Araujo, CRC  
❖ Fanny Gully, CRC

**CURRENTLY ENROLLING CLINICAL TRIALS - SUNRISE NEUROLOGY**

**Biogen: Affinity: Multiple Sclerosis**

An 18-month placebo controlled monthly IV study to evaluate an add on therapy for Relapsing Remitting or Secondary Progressive MS, must be 18-58 years of age, and be treated with one of the following DMTs for 6 months prior to baseline: Avonex, Plegridy, Betaseron, Rebif, Techfidera or Tysabri-Subjects will continue on their current therapy throughout the study. A relapse or new lesion (enhancing or T2) within the last 24 months is also part of inclusion criteria.

**Novartis-COMB: Multiple Sclerosis**

A 2-year study for Multiple Sclerosis to evaluate an investigational monthly IV medication vs. Teriflunomide. Participants must be 18-55 years of age, with Relapsing Remitting or Secondary progressive MS.

**Novartis-FLUENT: Multiple Sclerosis**

A 1 year observational study for patients either taking Gilenya for 2 consecutive years or newly prescribed. Only blood draws and questionnaires required.

**To participate or refer a patient --Call 954-475-8171 Ext 134 (Michele)**

3537 North Pine Island Road ❖ Sunrise, Florida 33351  
Phone: (954)738-1680 Fax: (954)738-1682  
❖ [www.infinityclinicalresearch.com](http://www.infinityclinicalresearch.com)